# Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

> **NCT01157156** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 51 (actual)

## Conditions studied

- Peripheral Arterial Occlusive Disease

## Interventions

- **DRUG:** XRP0038 (NV1FGF)

## Key facts

- **NCT ID:** NCT01157156
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-06
- **Primary completion:** 2001-09
- **Final completion:** 2001-09
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2010-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01157156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01157156, "Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01157156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*